These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 25862647

  • 1. Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.
    Baert F, Kondragunta V, Lockton S, Vande Casteele N, Hauenstein S, Singh S, Karmiris K, Ferrante M, Gils A, Vermeire S.
    Gut; 2016 Jul; 65(7):1126-31. PubMed ID: 25862647
    [Abstract] [Full Text] [Related]

  • 2. Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay.
    Rubin DT, Naik S, Kondragunta V, Rao T, Jain A.
    Curr Med Res Opin; 2017 May; 33(5):837-843. PubMed ID: 28145781
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
    Bodini G, Giannini EG, Savarino V, Del Nero L, Pellegatta G, De Maria C, Baldissarro I, Savarino E.
    Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
    [Abstract] [Full Text] [Related]

  • 6. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.
    Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M.
    Aliment Pharmacol Ther; 2018 Oct; 48(7):731-739. PubMed ID: 30109889
    [Abstract] [Full Text] [Related]

  • 7. Exploring the use of adalimumab for patients with moderate Crohn's disease: subanalyses from induction and maintenance trials.
    Sandborn WJ, Colombel JF, Panés J, Castillo M, Robinson AM, Zhou Q, Yang M, Thakkar R.
    J Crohns Colitis; 2013 Dec; 7(12):958-67. PubMed ID: 23517933
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.
    Imaeda H, Takahashi K, Fujimoto T, Bamba S, Tsujikawa T, Sasaki M, Fujiyama Y, Andoh A.
    J Gastroenterol; 2014 Jan; 49(1):100-9. PubMed ID: 23575576
    [Abstract] [Full Text] [Related]

  • 10. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
    Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben-Horin S, Chowers Y.
    Aliment Pharmacol Ther; 2014 Sep; 40(6):620-8. PubMed ID: 25039584
    [Abstract] [Full Text] [Related]

  • 11. Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease.
    Bodini G, Giannini EG, Furnari M, Marabotto E, Baldissarro I, Del Nero L, Assandri L, Moscatelli A, Savarino V, Savarino E.
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):451-6. PubMed ID: 26697571
    [Abstract] [Full Text] [Related]

  • 12. Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay.
    Wang SL, Hauenstein S, Ohrmund L, Shringarpure R, Salbato J, Reddy R, McCowen K, Shah S, Lockton S, Chuang E, Singh S.
    J Pharm Biomed Anal; 2013 May 05; 78-79():39-44. PubMed ID: 23454676
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.
    Nakase H, Motoya S, Matsumoto T, Watanabe K, Hisamatsu T, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T, DIAMOND study group.
    Aliment Pharmacol Ther; 2017 Nov 05; 46(9):873-882. PubMed ID: 28884856
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.